News
Video
Author(s):
Expert oncologists discuss the nuances of managing toxicities associated with Cabozantinib and Nivolumab combination therapy for advanced renal cell carcinoma (RCC).
Maughan Spotlights Ways to Reengage the Immune System and Debulking Approaches in RCC
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
Perioperative Nivolumab Regimen Improves EFS, Resection Rates in Stage III N2/non-N2 NSCLC
FDA Approval Insights: Ponatinib in Ph+ ALL
Consolidation Durvalumab to Become New SOC for LS-SCLC After Chemoradiation
Revisit Every OncLive On Air Episode From May 2024
JNJ-6420 Elicits Responses in mCRPC, But Safety Concerns Arise
ARV-766 Demonstrates Clinical Activity in AR LBD–Mutated Metastatic CRPC
MammaPrint High 2 Indication Could Be Predictive Biomarker for Immunotherapy in HR+/HER2– Early Breast Cancer
Linvoseltamab Generates Efficacy Similar to That Seen With Teclistamab in R/R Myeloma